시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
메트로니다졸(Metronidazole) 시장 보고서(2025년)
Metronidazole Global Market Report 2025
상품코드 : 1815888
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

메트로니다졸 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년 연평균 복합 성장률(CAGR)은 5.5%를 나타내 7억 6,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 박테리아 및 원충 감염의 유병률 증가, 위장 질환의 증례 증가, 저렴한 제네릭 항생제에 대한 수요 증가, 건강 관리 인프라 확대, 전염병 대책에 대한 정부의 이니셔티브 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 의약품 제조의 진보, 제약기업간의 전략적 제휴, 의약품 제조 수탁기관의 확대, 나노기술에 기초한 약물전달 시스템의 채용, pH 응답성 제제의 진보 등을 들 수 있습니다.

향후 5년간의 성장률 5.5%라고 하는 예측은 이 시장의 전회 예측으로부터 0.4%라는 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 중국과 이탈리아에서 수입되는 니트로이미다졸계 항생제의 원약이나 배합외용제의 비용을 밀어 올려 기생충이나 혐기성균 감염증의 치료비를 악화시켜 처방전의 소매가격을 올리기 때문에 미국 약국에 부담을 강하게 할 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

박테리아 감염의 이환율 증가는 메트로니다졸 시장 성장을 가속할 것으로 예측됩니다. 박테리아 감염은 신체의 유해한 박테리아의 증식에 의해 발생하며, 만연증 증가는 항생제 내성, 환경 변화, 면역 결핍 인구 증가 등의 요인으로 인해 발생합니다. 메트로니다졸은 박테리아의 DNA를 표적으로 하고 그 복제와 확산을 저해함으로써 혐기성 세균이나 특정 원충 감염에 대해 높은 효과를 발휘합니다. 예를 들어 영국 정부 기관인 UK Health Security Agency(UKHSA)에 따르면 2022년에는 영국에서 5만 8,224명이 항생제 내성 감염에 걸렸으며 2021년 5만 5,792례에서 4% 증가했습니다. 또한 심한 항생제 내성 감염으로 인한 사망자는 2021년 2,110명에서 2022년 2,202명으로 증가했습니다. 그 결과, 박테리아 감염의 유병률 증가가 메트로니다졸 시장 확대를 촉진할 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Metronidazole is an antibiotic and antiprotozoal medication used to treat bacterial and parasitic infections. It functions by penetrating microbial cells, where bacterial and protozoal enzymes reduce it, producing reactive nitrogen species. These reactive compounds damage DNA, leading to strand breakage and the inhibition of nucleic acid synthesis, ultimately disrupting replication and transcription, resulting in cell death.

The primary formulations of metronidazole include tablets, capsules, intravenous (IV) solutions, topical creams or ointments, and others. Metronidazole tablets are oral medications used to treat bacterial and parasitic infections, providing sustained effects for convenient and effective outpatient treatment. They are utilized for various applications, including bacterial infections, parasitic infections, gynecological infections, surgical prophylaxis, and more. The drug is distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. It is used by various end-users, including hospitals, clinics, homecare, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The metronidazole market research report is one of a series of new reports from The Business Research Company that provides metronidazole market statistics, including the metronidazole industry global market size, regional shares, competitors with the metronidazole market share, detailed metronidazole market segments, market trends, and opportunities, and any further data you may need to thrive in the metronidazole industry. This metronidazole market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metronidazole market size has grown strongly in recent years. It will grow from $0.58 billion in 2024 to $0.61 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to favorable healthcare reimbursement policies, increasing funding for infectious disease research, a growing incidence of oral and dental infections, a rising prevalence of inflammatory bowel diseases, and a growing elderly population.

The metronidazole market size is expected to see strong growth in the next few years. It will grow to $0.76 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to the increasing prevalence of bacterial and protozoal infections, rising cases of gastrointestinal disorders, growing demand for affordable generic antibiotics, expanding healthcare infrastructure, and government initiatives to combat infectious diseases. Major trends in the forecast period include advancements in pharmaceutical manufacturing, strategic collaborations between pharmaceutical companies, expansion of pharmaceutical contract manufacturing organizations, adoption of nanotechnology-based drug delivery systems, and advancements in pH-responsive metronidazole formulations.

The forecast of 5.5% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. pharmacies by driving up the cost of nitroimidazole antibiotic bulk active pharmaceutical ingredient and compounded topical formulations imported from China and Italy, exacerbating parasitic and anaerobic infection treatment costs and increasing retail prescription prices. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of bacterial infections is expected to drive the growth of the metronidazole market. Bacterial infections occur due to the proliferation of harmful bacteria in the body, and their increasing prevalence is attributed to factors such as antibiotic resistance, environmental changes, and a growing immunocompromised population. Metronidazole works by targeting bacterial DNA, disrupting its replication and spread, making it highly effective against anaerobic bacteria and certain protozoal infections. For instance, according to the UK Health Security Agency (UKHSA), a UK-based government agency, an estimated 58,224 individuals in England were affected by antibiotic-resistant infections in 2022, marking a 4% increase from 55,792 cases in 2021. Additionally, deaths from severe antibiotic-resistant infections rose from 2,110 in 2021 to 2,202 in 2022. As a result, the growing prevalence of bacterial infections is expected to fuel the expansion of the metronidazole market.

Key players in the metronidazole market are focusing on advancing drug formulations to improve patient compliance. Innovations such as ready-to-use oral liquids are being developed to enhance ease of administration, particularly for patients who have difficulty swallowing tablets or require a more convenient treatment option. Ready-to-use oral liquids eliminate the need for additional preparation or mixing, simplifying medication adherence. For example, in November 2023, Kesin Pharma Corporation, a US-based specialty pharmaceutical company, received FDA approval for LIKMEZ (metronidazole) oral suspension, 500 mg/5 mL. This novel formulation is designed to improve patient adherence and is approved for treating trichomoniasis and anaerobic bacterial infections in adults, as well as amebiasis in adults and children. LIKMEZ is available as a strawberry peppermint-flavored suspension in a 200 mL bottle with a 24-month shelf life and does not require refrigeration.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired a manufacturing facility from Teva Pharmaceutical Industries for an undisclosed amount. This acquisition is expected to double Marksans' existing production capacity from 8 billion units per year. Teva Pharmaceutical Industries is an India-based pharmaceutical company that manufactures metronidazole tablets.

Major players in the metronidazole market are Pfizer Inc., Merck & Co. Inc., Abbott Laboratories, Fresenius Kabi AG, Baxter International Inc., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., Zydus Lifesciences, YiChang HEC ChangJiang Pharmaceutical Co. Ltd., Aarti Drugs Ltd., Unichem Laboratories, Cosette Pharmaceuticals Inc., Saptalis Pharmaceuticals LLC, Huanggang Saikang Pharmaceutical Co. Ltd., Kesin Pharma, Hubei Hongyuan Pharmaceutical Technology Co. Ltd., Huanggang Yinhe Aarti Pharmaceutical Co. Ltd., and Higgs Healthcare.

Asia-Pacific was the largest region in the metronidazole market in 2024. The regions covered in metronidazole report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metronidazole market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metronidazole market consists of sales of oral suspension, suppositories, and gel. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metronidazole Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metronidazole market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for metronidazole ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metronidazole market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Metronidazole Market Characteristics

3. Metronidazole Market Trends And Strategies

4. Metronidazole Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Metronidazole Growth Analysis And Strategic Analysis Framework

6. Metronidazole Market Segmentation

7. Metronidazole Market Regional And Country Analysis

8. Asia-Pacific Metronidazole Market

9. China Metronidazole Market

10. India Metronidazole Market

11. Japan Metronidazole Market

12. Australia Metronidazole Market

13. Indonesia Metronidazole Market

14. South Korea Metronidazole Market

15. Western Europe Metronidazole Market

16. UK Metronidazole Market

17. Germany Metronidazole Market

18. France Metronidazole Market

19. Italy Metronidazole Market

20. Spain Metronidazole Market

21. Eastern Europe Metronidazole Market

22. Russia Metronidazole Market

23. North America Metronidazole Market

24. USA Metronidazole Market

25. Canada Metronidazole Market

26. South America Metronidazole Market

27. Brazil Metronidazole Market

28. Middle East Metronidazole Market

29. Africa Metronidazole Market

30. Metronidazole Market Competitive Landscape And Company Profiles

31. Metronidazole Market Other Major And Innovative Companies

32. Global Metronidazole Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metronidazole Market

34. Recent Developments In The Metronidazole Market

35. Metronidazole Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기